Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof

US10722501B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Nicole BIBER · Wuppertal, DE
• Damian Brockschnieder · Haan, DE
• Kersten Matthias Gericke · Wuppertal, DE
• Florian Kölling · Wuppertal, DE
• Klemens Lustig · Wuppertal, DE
• Jörg Meding · Wuppertal, DE
• Heinrich Meier · Wuppertal, DE
• Thomas Neubauer · Wuppertal, DE
• Martina Schäfer · Berlin, DE
• Andreas TIMMERMANN · Düsseldorf, DE
• Dmitry Zubov · Remscheid, DE
• Carsten TERJUNG · Bochum, DE
• Niels Lindner · Wuppertal, DE
• Volker BADOCK · Berlin, DE
• Dieter MOOSMAYER · Berlin, DE
• Hideki Miyatake Ondozabal · Berlin, DE
• Stephen Moore · Edmonton, CA
• Alexander Schulz · Rietberg, DE

Key dates

• Filing date: May 8, 2017
• Grant date: Jul 28, 2020
• Expiry date: May 8, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.